期刊文献+

噬菌体对小鼠肠源性铜绿假单胞菌感染的治疗作用 被引量:3

Therapeutic effect of bacteriophage on intestine-derived infection caused by Pseudomonas aeruginosa in mice
暂未订购
导出
摘要 目的:探讨铜绿假单胞菌噬菌体对小鼠肠源性铜绿假单胞菌感染的治疗作用,以阐明噬菌体潜在的应用价值。方法:利用噬斑法从居民生活污水中分离和鉴定铜绿假单胞菌噬菌体,用氨苄青霉素造成小鼠肠道菌群失调同时注射环磷酰胺使小鼠免疫功能下降,通过口服铜绿假单胞菌建立动物感染模型。将动物分为治疗组Ⅰ(在感染前1 d给予噬菌体)、治疗组Ⅱ(在感染的第5天给予噬菌体)、治疗组Ⅲ(在感染的第10天给予噬菌体)和对照组(不给予噬菌体),观察噬菌体的抗感染疗效。结果:采用噬斑法分离和纯化4株铜绿假单胞菌噬菌体。电镜显示噬菌体头部呈立体对称,有一短尾。在肠源性铜绿假单胞菌感染的动物模型中,小鼠的死亡率为100%。治疗组Ⅰ小鼠存活率为70%,与对照组比较差异有显著性(P<0.01)。治疗组Ⅱ小鼠存活率为80%,与对照组比较差异亦有显著性(P<0.01)。在感染的第10天给予噬菌体治疗,小鼠存活率降至10%,与对照组比较差异无显著性(P>0.05)。结论:早期应用噬菌体对铜绿假单胞菌引起的肠源性感染有明显的治疗作用,提示噬菌体可以作为一种新型的抗感染生物制剂。 Objective To explore the application of bacteriophage therapy against intestine-derived infection caused by Pseudomonas aeruginosa and to evaluate the potential value of bacteriophages.Methods Phages were isolated and purified by conventional processes.A murine model of intestine-derived infection caused by Pseudomonas aeruginosa was established through administration of ampicillin and cyclophosphamide(CY) by intraperitoneal injection.Animals were divided into treatment group Ⅰ(phage administration,1 d before the bacterial challenge),treatment group Ⅱ(phage administration,5 d after the bacterial challenge),treatment group Ⅲ(phage administration,10 d after the bacterial challenge) and control group(no phage administration) to evaluate anti-infection efficacy of phage.Results Four strains of lytic phage were isolated from sewage.1 d before the bacteria challenge,oral administration of lytic phages was sufficiently to rescue 70% of the animals compared with control animals(P〈0.01).5 dafter the bacteria challenge,oral administration of lytic phages was significantly to rescue 80% of the animals compared with control animals(P〈0.01).However,10 d after the bacteria challenge,oral administration of lytic phages was only to rescue 10% of the animals(P〉0.05).Conclusion The phage treatment significantly improve the survival rate of mice during the early stage of infection;it suggestes that the phages may serve as an effective agent against bacterial infection.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2009年第4期660-663,766,共5页 Journal of Jilin University:Medicine Edition
基金 吉林省科技厅科研基金资助课题(200705374)
关键词 铜绿假单胞菌 噬菌体 抗感染疗法 Pseudomonas aeruginosa bacteriophage anti-infection therapy
  • 相关文献

参考文献10

  • 1陈民钧,王辉,中国医院内病原菌耐药监测网.中国重症监护病房革兰阴性菌耐药性连续7年监测研究[J].中华医学杂志,2003,83(5):375-381. 被引量:504
  • 2MatsumotoT, Tateda K, Miyazaki S, et al. Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice [J]. Antimicrob Agents Chemother, 1998, 42 (11): 2853-2857.
  • 3Watanabe R, Matsumoto T, Sano G, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice [J]. Antimicrob Agents Chemother, 2007, 51 (2): 446-452.
  • 4Hermoso JA, Garcia JL, Gareia P. Taking aim on bacterial pathogens: from phage therapy to enzybiotics [J]. Curr Opin Microbiol, 2007, 10 (5): 461-472.
  • 5Merri CR, Scholl D, Adhya SL. The prospect for bacteriophage therapy in Western Medicine [ J]. Nat Rev Drug Discov, 2003, 2 (6): 489-497.
  • 6Skurnik M, Strauch E. Phage therapy: facts and fiction [J]. Int J Med Microbiol, 2006, 296 (1) : 5-14.
  • 7Barrow P, Lovell M, Berchieri A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves [J]. Clin Diagn Lab Immunol, 1998, 5 (3): 294-298.
  • 8Jamalludeen N, Johnson R, Friendship R, et al. Isolation and characterization of nine bacteriophages that lyse O149 enterotoxigenic Escherichia coli [J]. Vet Microbiol, 2007, 20 (124): 47-57.
  • 9Biswas B, Adhya S, Washart P, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of Vancomycin-resistant Enterococcus faecium [J ]. Infect Immunol, 2002, 70 (1): 204-210.
  • 10Sandeep K. Bacteriophage precision drug against bacterial infection[J]. Curr Sci, 2006, 90 (5): 361-363.

二级参考文献10

  • 1Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
  • 2Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.
  • 3Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in gram-negative isolates from ICU in Turkey:analysis of data from the last 5 years. J Chemother, 2002, 14:140-146.
  • 4Karlowsky JA, Kelly LJ, Thornsberry C , et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000:TRUST and TSN data for the United States. J Autimicrob Agents , 2002,19: 21-31.
  • 5National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. National Committee for Clinical Laboratory Standards,Wayne, Pa.2002,1.
  • 6Chanawong A. M' Zali FH, Heritage J, et al. Three cefotaximases,CTX-M-9, CTX-M-13, CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother, 2002, 46:630-637.
  • 7朱戌冬,徐英春,吴伟元,王辉,陈民钧.一种新CTX-M型超广谱β-内酰胺酶及其临床意义[J].中华检验医学杂志,2001,24(4):207-210. 被引量:47
  • 8王辉,吴伟元,陈民钧.肠杆菌科细菌中超广谱β-内酰胺酶(ESBL)的研究[J].中华微生物学和免疫学杂志,2001,21(6):676-679. 被引量:99
  • 9佘丹阳,刘又宁.AmpC酶和超广谱β-内酰胺酶在阴沟肠杆菌中的表达及对其耐药性的影响[J].中华医学杂志,2002,82(19):1355-1358. 被引量:86
  • 10吴伟元,陈民钧,王辉.阴沟肠杆菌6株中产超广谱β内酰胺酶的基因型[J].中国抗感染化疗杂志,2001,1(3):155-159. 被引量:15

共引文献503

同被引文献45

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部